The “Center for AI-Accelerated Molecular Innovations in Medicine” (AI2M) is being established at the Max Delbrück Center in Berlin. It is being funded with 30.8 million euros from the Helmholtz Association. The aim is to develop AI-based strategies for the precise prevention and treatment of diseases in order to maintain health for as long as possible in an ageing society. To this end, molecular and cellular changes from a healthy to a diseased state are to be precisely understood.

According to the researchers, they will analyze large molecular and clinical data sets from healthy individuals and patients. The aim is to use advanced AI models to identify patterns and mechanisms that will enable new diagnostic procedures, therapies and preventive measures. AI2M comprises two locations: A hub for spatial and single-cell-based biomedicine and AI will be built in Berlin-Mitte from 2026, with construction due to be completed in 2029. A hub for models with human cells and bioengineering will follow in Berlin-Buch in 2033.

The highlight: in future, interdisciplinary teams from research, industry and clinics will be able to access extensive population studies in order to identify biomarkers for early indicators of disease and develop targeted therapies. Technologies such as spatial multi-omics approaches and high-throughput screening platforms for organoids, developed by researchers at the Max Delbrück Center, will enable precise mapping of disease progression and testing of personalized treatments. Partners such as the Charité and the Berlin Institute of Health are supporting the rapid implementation in clinical practice.

“Medicine is changing. It will no longer just react to symptoms, but make predictions. Innovation centers such as AI2M will play a central role in this transformation. Very early diagnosis as well as personalized and more effective interventions should not only be possible, but also become part of everyday medical practice,” says Professor Maike Sander, Scientific Director of the Max Delbrück Center and Vice President of Helmholtz Health.

The center combines AI, biology, engineering and medicine to promote innovation at the interfaces between the disciplines. The aim is to establish early diagnoses and personalized interventions in everyday medical practice in order to prevent diseases before they cause symptoms.

Read also:

Artificial intelligence supports joint decision-making in medicine – MedLabPortal

Editorial office: X-Press Journalistenbüro GbR

Gender note. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple references and gendered designations are avoided for the sake of better readability ected.